Table 4.
Glycemic measures
| Persons with diabetes | Persons without diabetes | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Study | Drug | HbA1C | Plasma Glucose | Insulin | HOMA-IR | HbA1C | Plasma glucose | Insulin | HOMA-IR |
| ILLUMINATE23 | Torcetrapib | At 12 mo: placebo arm (n = 2999) 7.36%; CETPi arm (n = 2796) 7.16% (P < 0.001) | At 3 mo: 0.34 mmol/L lower in CETPi arm (n = 3137) than placebo arm (n = 3288) (P < 0.001) | At 3 mo: 11.7 μU/mL lower in CETPi arm (n = 3092) than placebo arm (n = 3230) (P < 0.0001) | At 3 mo: Decreased from 49.1 to 47.3 in CETPi arm (n = 3053) (P < 0.0001), increase in placebo arm (n = 3200) | At 12 mo: placebo arm (n = 240) 6.52%; CETPi (n = 219) 6.27% (p<0.001) | At 12 mo: –0.06 Placebo (n = 3857)-CETPi (n = 3972) (P = 0.03) | At 3 mo: 6.6 lower in CETPi arm (n = 3092) than placebo arm (n = 3947) (P < 0.001) | At 3 mo: Decreased from 22.35 to 21.89 in CETPi arm (n = 4026) while increase in placebo arm (n = 3906) |
| Dal-OUTCOMES20 | Dalcetrapib | Not reported | Not reported | Not reported | Not reported | At 12 mo: placebo arm (n = 6923) 5.9%; CETPi (n = 6847) 5.8%, (P < 0.01)* | At 12 mo: 5.6 mmol/L in placebo arm (n = 5397); CETPi arm (n = 5297) (P > 0.05)* | At 3 mo: –0.61 μU/mL CETPi (n = 1071)-Placebo (n = 1097) (P > 0.05) | At 3 mo: Placebo (n = 1097) 2.09; CETPi (n = 1071) 1.95 (P > 0.05) |
| ACCELERATE19 | Evacetrapib | At 6 mo: placebo arm 7.15%; CETPi arm 7.08% (P = 0.023) | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported | Not reported |
| REVEAL8 | Anacetrapib | Placebo arm 6.9%; CETPi arm 6.9% (P = 0.92) (n = NR)† | Not reported | Not reported | Not reported | –0.03 CETPi-placebo (P < 0.001) (n = NR)† | Not reported | Not reported | Not reported |
| DEFINE11 | Anacetrapib | At 76 w: CETPi-placebo: –0.11 (P = 0.083) (n = NR) | Not reported | Not reported | Not reported | Not reported | At 76 w: –2.5 CETPi-Placebo (P = 0.11) (n = NR) | Not reported | Not reported |
DEFINE showed changes in HbA1C between CETPi and placebo groups, but the results of the two groups were not individually reported. Green = significant improvement, Yellow = trending towards improvement, Red = no effect. HbA1C, haemoglobin A1C; HOMA-IR, Homeostatic model assessment of insulin resistance; DM, baseline cohort of persons with diabetes; NDM, baseline persons without diabetes; NR, not reported.
*This data reflects the whole cohort (DM + NDM), as majority of dal-OUTCOMES cohort is NDM, it is most representative of this group.
†Data collected at final study visit, precise timing not reported.